Skip to main content
GutCited

N-Acetyl Cysteine (NAC) Abbildungen

13 Abbildungen aus begutachteter Forschung

Alle Saccharomyces boulardii Lactobacillus acidophilus Bifidobacterium lactis Lactobacillus plantarum Bifidobacterium longum Bifidobacterium bifidum Lactobacillus gasseri Bacillus coagulans Inulin Fructooligosaccharides (FOS) Galactooligosaccharides (GOS) Psyllium Husk Lactase Pancreatic Enzymes (Pancrelipase) Alpha-Galactosidase L-Glutamine N-Acetyl Cysteine (NAC) Peppermint Oil Ginger Berberine Curcumin Zinc Vitamin D Vitamin A Butyrate (Sodium/Calcium Butyrate) Omega-3 Fatty Acids (EPA/DHA) Medium-Chain Triglycerides (MCT Oil) Bovine Colostrum Aloe Vera (Inner Leaf Gel)
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Fig. 2 Characterization of TDNPs. A TDNPs were isolated and purified by sucrose gradient ultracentrifugation, band 1 from 8%/30% interface was named TDNPs 1, and band 2 from 30%/45% interface was named TDNPs 2. B Transmission Electron Microscopy (TEM) to
Figure 2 Chart

Characterization of turmeric-derived nanoparticles reveals two distinct bands (TDNPs 1 and TDNPs 2) at the 8%/30% and 30%/45% sucrose gradient interfaces, respectively. TDNPs 2 demonstrate appropriate size distribution and surface charge for oral drug delivery applications.

Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for …

Figure 3
Figure 3 Chart

In vitro assessment of turmeric-derived nanovesicles demonstrates anti-inflammatory activity, including suppression of pro-inflammatory cytokine production in activated macrophages. Dose-dependent reductions in TNF-alpha and IL-6 secretion are observed.

Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for …

Figure 5
Figure 5 Chart

Oral TDNPs 2 administration significantly attenuates disease activity index scores and colon shortening in DSS-induced colitis mice. Body weight recovery is also improved compared to untreated colitis controls.

Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for …

Figure 6
Figure 6 Chart

Intestinal permeability assessment indicates that TDNPs 2 treatment preserves gut barrier integrity in colitis mice. Tight junction protein expression, including ZO-1 and occludin, is maintained at near-normal levels.

Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for …

Fig. 8 Oral administration of TDNPs 2 accelerated inflammation resolution of colitis. A ECIS wound healing assay. B Lcn-2 quantification (n= 5).
Figure 8 Chart

Wound healing assays and fecal lipocalin-2 quantification demonstrate that TDNPs 2 accelerate resolution of intestinal inflammation. Lcn-2 levels, a sensitive marker of intestinal inflammation, decrease significantly with treatment.

Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for …

Fig. 9 Biocompatibility evaluation of TDNPs 2. A Vital organs weights (n= 5). B Pro-inflammatory cytokines (n= 5). C Indicators reflected the physiological function of the liver were evaluated. D H&E staining, scale bar: 50 μm
Figure 9 Chart

Biocompatibility evaluation shows no significant changes in vital organ weights, pro-inflammatory cytokines, or liver function indicators in TDNPs 2-treated mice. H&E staining of major organs confirms absence of toxicity.

Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for …

Fig. 10 TDNPs 2 exerted a protective effect by inactivating the NF-κB pathway. A NF-κB activity evaluation (n= 5). B Phospho-NF-κB p65 expression was evaluated by ELISA assay (n= 5). C The translocation of NF-kB-p65 to the nucleus was assessed by immunofl
Figure 10 Chart

TDNPs 2 exert their protective effect at least partly through inactivation of the NF-kB signaling pathway. Reduced phospho-NF-kB p65 expression and decreased nuclear translocation indicate suppression of this key inflammatory cascade.

Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for …

Figure 7
Figure 7 Chart

Quantification of DNA double-strand break repair efficiency in H. pylori-infected gastric cells, indicating that alpha-lipoic acid supports the Ku-dependent non-homologous end joining pathway.

α-Lipoic Acid Inhibits Apoptosis by Suppressing the Loss of Ku Proteins in …

Figure 8
Figure 8 Chart

Cell viability analysis across different alpha-lipoic acid concentrations in H. pylori-infected gastric epithelial cells, establishing the effective dose range for cytoprotection.

α-Lipoic Acid Inhibits Apoptosis by Suppressing the Loss of Ku Proteins in …

Figure 4
Figure 4 Chart

Oxidative stress biomarkers measured in colon, liver, and kidney tissues, comparing malondialdehyde (MDA) and glutathione (GSH) levels across treatment groups.

Extraintestinal Manifestations in Induced Colitis: Controversial Effects of N-Acetylcysteine on Colon, Liver, …

Figure 5
Figure 5 Chart

Inflammatory cytokine levels (such as TNF-alpha, IL-6, or IL-1beta) in colonic and extraintestinal tissues, assessing whether NAC modulates systemic inflammation originating from the gut.

Extraintestinal Manifestations in Induced Colitis: Controversial Effects of N-Acetylcysteine on Colon, Liver, …

Figure 6
Figure 6 Chart

Colon length measurements and macroscopic damage scoring in the colitis model, providing gross anatomical evidence of disease severity and NAC treatment response.

Extraintestinal Manifestations in Induced Colitis: Controversial Effects of N-Acetylcysteine on Colon, Liver, …

Figure 7
Figure 7 Chart

Summary of controversial findings regarding NAC's differential effects across organs, with protective trends observed in some tissues but potential adverse signals in others.

Extraintestinal Manifestations in Induced Colitis: Controversial Effects of N-Acetylcysteine on Colon, Liver, …